Safety concerns and health benefits associated with oral contraception

American Journal of Obstetrics and Gynecology

Volumn 190, Issue 4 SUPPL., 2004, Pages

  Burkman, Ronald ^a   Schlesselman, James J ^b   Zieman, Miriam ^c  

^a BAYSTATE MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular effects; Neoplastic effects; Noncontraceptive health benefits; Oral contraceptives

Indexed keywords

DANAZOL; DESOGESTREL; DROSPIRENONE; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ETHINYLESTRADIOL PLUS NORGESTIMATE; GESTAGEN; GESTODENE; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MEFENAMIC ACID; NAPROXEN; NORETHISTERONE; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT;

ACNE; ASTHMA; BONE MASS; BREAST CANCER; BREAST FIBROADENOMA; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLON CANCER; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DYSMENORRHEA; ECTOPIC PREGNANCY; ENDOMETRIOSIS; ENDOMETRIUM CANCER; EPIDEMIOLOGICAL DATA; FEMALE; FIBROCYSTIC BREAST DISEASE; GALLBLADDER CANCER; HEART INFARCTION; HORMONAL CONTRACEPTION; HUMAN; IRON DEFICIENCY ANEMIA; KIDNEY CANCER; LEG THROMBOSIS; LIVER CANCER; LUNG EMBOLISM; MATHEMATICAL ANALYSIS; MELANOMA; META ANALYSIS; METRORRHAGIA; MIGRAINE; OLIGOMENORRHEA; ORAL CONTRACEPTION; OVARY CANCER; OVARY CYST; OVULATION INHIBITION; PORPHYRIA; PREDICTION; PRIORITY JOURNAL; RECTUM CANCER; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SALPINGITIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STROKE; SYSTEMATIC REVIEW; UTERINE CERVIX CANCER; VENOUS THROMBOEMBOLISM;

EID: 2342435372     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2004.01.061     Document Type: Article

References (105)

1. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of an international multicentre case-control study. Lancet 1995;346:1575-82.
2. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Acute myocardial infarction and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 1997;349:1202-9.
3. WHO. Cardiovascular Disease and Steroid Hormone Contraception: report of a WHO Scientific Group. Geneva, Switzerland: WHO Scientific Group on Cardiovascular Disease and Steroid Hormone Contraception; 1998. WHO Technical Report No. 877.
4. Nightingale A, Lawrenson R, Simpson E, Williams T, MacRae K, Farmer R. The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives. Eur J Contracept Reprod Health Care 2000;5:265-74.
5. Gerstman B, Piper J, Tomita D, Ferguson W, Stadel B, Lundin F. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991;133:32-6.
6. Porter J, Hunter J, Jick H, Stergachis A. Oral contraceptives and nonfatal vascular disease. Obstet Gynecol 1985;66:1-4.
7. Farmer R, Preston T. The risk of venous thromboembolism associated with low oestrogen oral contraceptives. J Obstet Gynaecol 1995;15:195-200.
8. Thorogood M, Mann J, Murphy M, Vessey M. Risk factors for fatal venous thromboembolism in young women: a case- control study. Int J Epidemiol 1992;21:48-52.
9. Vandenbroucke JP, Koster T, Briet E, Reitsma P, Bertina R, Rosendaal FR. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-7.
10. Lewis M, Heinemann L, MacRae K, Bruppacher R, Spitzer W. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women. Contraception 1996;54:5-13.
11. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995;346:1593-6.
12. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995;346:1589-93.
13. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996;312:83-8.
14. Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997;349:83-8.
15. Jick H, Kaye JA, Vasilakis-Scaramozza C, Jick SS. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ 2000;321:1190-5.
16. Mishell DJ. Comprehensive gynecology. 3rd ed. St. Louis: Mosby-Year Book; 1997 p. 302.
17. Winkler U. Blood coagulation and oral contraceptives: a critical review. Contraception 1998;57:203-9.
18. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina R. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993;342:1503-6.
19. Svensson P, Dahlbac B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330:517-22.
20. Altes A, Souto JC, Mateo J, Borrell M, Fontcuberta J. Activated protein C resistance assay when applied in the general population. Am J Obstet Gynecol 1997;176:358-9.
21. Creinen MD, Lisman R, Strickler RC. Screening for factor V Leiden mutation before prescriving combination oral contraceptives. Fertil Steril 1999;72:646-51.
22. Speroff L, DeCherney A. Evaluation of a new generation of oral contraceptives. The Advisory Board for the New Progestins. Obstet Gynecol 1993;81:1034-47.
23. Croft P, Hannaford P. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' oral contraceptive study. BMJ 1989;298:165-8.
24. Rosenberg L, Palmer J, Lesko S, Shapiro S. Oral contraceptive use and the risk of myocardial infarction. Am J Epidemiol 1990;131:1009-16.
25. Castelli W. Cardiovascular disease: pathogenesis, epidemiology, and risk among users of oral contraceptives who smoke. Am J Obstet Gynecol 1999;180(Pt 2):S349-56.
26. Deslypere J, Thiery M, Vermeulen A. Effect of long-term hormonal contraception on plasma lipids. Contraception 1985;31:633-42.
27. Mishell DR Jr. Oral contraception: past, present, and future perspectives. Int J Fertil 1991;36(suppl):7-18.
28. Mann J. Progestogens in cardiovascular diseases: an introduction to the epidemiologic data. Am J Obstet Gynecol 1982;142:752-7.
29. Godsland I, Crook D. Update on the metabolic effects of steroidal contraceptives and their relationship to cardiovascular disease risk. Am J Obstet Gynecol 1994;170:1528-36.
30. WHO. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 1996;348:498-505.
31. Schwartz SM, Petitti DB, Siscovick DS, Longstreth WT Jr, Sidney S, Raghunathan TE, et al. Stroke and use of low-dose oral contraceptives in young women: a pooled analysis of two US studies. Stroke 1998;29:2277-84.
32. Lidegaard O. Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study. BMJ 1993;306:956-63.
33. Heinegmann L, Lewis M, Thorogood M, Spitzer W, Guggenmoos-Holzmann I, Bruppacher R. Case-control study of oral contraceptives and risk of thromboembolic stroke: results from international study on oral contraceptives and health of young women. BMJ 1997;315:1502-4.
34. Petitti DB, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel HK. Stroke in users of low-dose oral contraceptives. N Engl J Med 1996;335:8-15.
35. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Hemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 1996;348:505-10.
36. Schlesselman J, Collins J. The influence of steroids on gynecologic cancers. In: Fraser IS JR, Lobo RA, Whitehead MI, editors. Estrogens and progestogens in clinical practice. London: Churchill Livingstone; 1998. p. 831-64.
37. Schlesselman JJ. Net effect of oral contraceptive use on the risk of cancer in women in the United States. Obstet Gynecol 1995;85(Pt 1):793-801.
38. Walboomers J, Jacobs M, Manos M, Bosch F, Kummer J, Shah K, et al. Human papillomavirus is a necessary cause of invasice cervical cancer worldwide. J Pathol 1999;189:12-9.
39. Chen Y, Huang L, Chen T. Differential effects of progestins and estrogens on long control regions of human papillomavirus types 16 and 18. Biochem Biophys Res Commun 1996;224:651-9.
40. Bartholomew J, Glenville S, Sarkar S, Burt D, Stanley M, Ruiz-Cabello F, et al. Integration of high-risk human papillomavirus DNA is linked to the down-regulation of class I human leukocyte antigens by steroid hormones in cervical tumor cells. Can Res 1997;57:937-42.
41. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Hormonal contraception and post-menopausal hormonal therapy. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Lyon: IARC; 1999.
42. Connell E. Clinical aspects of oral contraception. In: Fraser IS JR, Lobo RA, Whitehead MI, editors. Estrogens and progestogens in clinical practice. London: Churchill Livingstone; 1998. p. 555-77.
43. Hannaford P, Kay C, Vessey M, Painter R, Mant J. Combined oral contraceptives and liver disease. Contraception 1997;55:145-51.
44. Hannaford P. Health consequences of combined oral contraceptives. Br Med Bull 2000;56:749-60.
45. Hankinson S, Stempfer M. Influence of therapeutic steroids on the incidence and severity of breast cancer. In: Fraser IS JR, Lobo RA, Whitehead MI, editors. Estrogens and progestogens in clinical practice. London: Churchill Livingstone; 1998. p. 865-78.
46. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual date on 53, 297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713-27.
47. King R. Biology of female sex hormone action in relation to contraceptive agents and neoplasia. Contraception 1991;43:527-42.
48. Clemons M, Goss M. Estrogen and the risk of breast cancer. N Engl J Med 2001;344:276-85.
49. Chen C, Weiss N, Newcomb P, Barlow W, White E. Hormone replacement therapy in relation to breast cancer. JAMA 2002;287:734-41.
50. Fernandez E, La Vecchia C, Balducci A, Chatenoud L, Franceschi S, Negri E. Oral contraceptives and colorectal cancer risk: a meta-analysis. Br J Cancer 2001;84:722-7.
51. Schlesselman JJ. Risk of endometrial cancer in relation to use of combined oral contraceptives: a practitioner's guide to meta-analysis. Hum Reprod 1997;12:1851-63.
52. Feuer E, Wu L. DEVCAN: probability of developing or dying of cancer. 4.0 ed. Bethesda (MD): National Cancer Institute; 1999.
53. Lambe M, Hsieh C, Trichopoulos D, Ekbom A, Pavia M, Adami H. Transient increase in the risk of breast cancer after giving birth. N Engl J Med 1994;331:5-9.
54. Wohlfahrt J, Andersen P, Mouridsen H, Melbye M. Risk of late-stage breast cancer after childbirth. Am J Epidemiol 2001:1079-84.
55. Shapiro S. Bias in the evaluation of low-magnitude associations: an empirical perspective. Am J Epidemiol 2000;151:939-45.
56. Chan W, Dawood M, Fuchs F. Prostaglandins in primary dysmenorrhea. Comparison of prophylactic and nonprophylactic treatment with ibuprofen and use of oral contraceptives. Am J Med 1981;70:535-41.
57. Milsom I, Sundell G, Andersch B. The influence of different combined oral contraceptives on the prevalence and severity of dysmenorrhea. Contraception 1990;42:497-506.
58. Hauksson A, Eikstrom P, Juchnicka E, Laudanski T, Akerlund M. The influence of a combined oral contraceptive on uterine activity and reactivity to agonists in primary dysmenorrhea. Acta Obstet Gynecol Scand 1989;68:31-4.
59. Larsson G, Milsom I, Lindstedt G, Rybo G. The influence of a low-dose combined oral contraceptive on menstrual blood loss and iron status. Contraception 1992;46:327-34.
60. Nilsson L, Solvell L. Clinical studies on oral contraceptives - a randomized double-blind cross-over study of 4 different preparations: Anovlar mite, Lyndiol mite, Ovulen, and Volidan. Acta Obstet Gynecol Scand 1967;Suppl 8:3-31.
61. Nilsson L, Rybo G. Treatment of menorrhagia. Am J Obstet Gynecol 1971;110:713-20.
62. Fraser I, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibition agents in women with a complaint of mehorrhagia. Aust NZ J Obstet Gynecol 1991;31:66-70.
63. Davis A, Godwin A, Lippman J, Olson W, Kafrissen M. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. Obstet Gynecol 2000;96:913-20.
64. Milman N, Kirchhoff M, Jorgensen T. Iron status markers, serum ferritin and hemoglobin in 1359 Danish women in relation to menstruation, hormonal contraception, parity, and postmenopausal hormone treatment. Ann Hematol 1992;65:96-102.
65. Milman N, Rosdahl N, Lyhne N, Jorgensen T, Graudal N. Iron status in Danish women aged 35-65 years: relation to menstruation and method of contraception. Acta Obstet Gynecol Scand 1993;72:601-5.
66. Milman N, Clausen J, Byg K. Iron status in 268 Danish women aged 18-30 years: influence of mestruation, contraceptive method, and iron supplementation. Ann Hematol 1998;77:13-9.
67. Galan P, Yoon HC, Preziosi P, Viteri F, Valeix P, Fieux B, et al. Determining factors in the iron status of adult women in the SU.VI.MAX study. Supplementation en VItamines et Mineraux AntioXydants. Eur J Clin Nutr 1998;52:383-8.
68. Ory H. Functional ovarian cysts and oral contraceptives: negative association confirmed surgically. JAMA 1974;228:68-9.
69. Ylikorhala O. Ovarian cysts and hormonal contraception. Lancet 1977;2:1101-2.
70. Walnut Creek Contraceptive Drug Study. A prospective study of the side effects of oral contraceptives. Bethesda (MD): National Institutes of Health; 1981.
71. Vessey M, Metcalfe A, Wells C, McPherson K, Westhoff C, Yeates D. Ovarian neoplasms, functional ovarian cysts, and oral contraceptives. Br Med J (Clin Res Ed) 1987;294:1518-20.
72. Booth M, Beral V, Maconcochie N, Carpenter L, Scott C. A case-control study of benign ovarian tumours. J Epidemiol Comm Health 1992;46:528-31.
73. Parazzini F, Moroni S, Negri E, La Vecchia C, Dal Pino D, Ricci E. Risk factors for functional ovarian cysts. Epidemiology 1996;7:547-9.
74. Chiaffarino F, Parazzini F, La Vecchia C, Ricci E, Crosignani PG. Oral contraceptive use and benign gynecologic conditions: a review. Contraception 1998;57:11-8.
75. Lanes SF, Birmann B, Walker AM, Singer S. Oral contraceptive type and functional ovarian cysts. Am J Obstet Gynecol 1992;166:956-61.
76. Grimes DA, Godwin AJ, Rubin A, Smith JA, Lacarra M. Ovulation and follicular development associated with three low-dose oral contraceptives: a randomized controlled trial. Obstet Gynecol 1994;83:29-34.
77. Peterson HB, Lee NC. The health effects of oral contraceptives: misperceptions, controversies, and continuing good news. Clin Obstet Gynecol 1989;32:339-55.
78. Mol BW, Ankum WM, Bossuyt PM, Van der Veen F. Contraception and the risk of ectopic pregnancy: a meta-analysis. Contraception 1995;52:337-41.
79. McGonigle KF, Huggins GR. Oral contraceptives and breast disease. Fertil Steril 1991;56:799-819.
80. Charreau I, Plu-Bureau G, Bachelot A, Contesso G, Guinebretiere JM, Le MG. Oral contraceptive use and risk of benign breast disease in a French case-control study of young women. Eur J Cancer Prev 1993;2:147-54.
81. Rohan TE, Miller AB. A cohort study of oral contraceptive use and risk of benign breast disease. Int J Cancer 1999;82:191-6.
82. Burkman RT. Oral contraceptives: current status. Clin Obstet Gynecol 2001;44:62-72.
83. Rubin GL, Ory HW, Layde PM. Oral contraceptives and pelvic inflammatory disease. Am J Obstet Gynecol 1982;144:630-5.
84. Wolner-Hansson P, Svensson L, Mardh P, Westrom L. Laparoscopic findings and contraceptive use in women with signs and symptoms suggestive of acute salpingitis. Obstet Gynecol 1985;66:233-8.
85. Wolner-Hansson P, Eschenbach D, Paavonen J, Kiviat N, Stevens C, Critchlow C, et al. Decreased risk of symptomatic chlamydial pelvic inflammatory disease associated with oral contraceptive use. JAMA 1990;263:54-9.
86. Ness RB, Keder LM, Soper DE, Amortegui AJ, Gluck J, Wiesenfeld H, et al. Oral contraception and the recognition of endometritis. Am J Obstet Gynecol 1997;176:580-5.
87. Ness R, Soper D, Holley R, Peipert J, Randall H, Sweet R, et al. Hormonal and barrier contraception and risk of upper genital tract disease in the PID Evaluation and Clinical Health (PEACH) Study. Am J Obstet Gynecol 2001;185:121-7.
88. Lucky AW, Henderson TA, Olson WH, Robisch DM, Lebwohl M, Swinyer LJ. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol 1997;37(Pt 1):746-54.
89. Redmond GP, Olson WH, Lippman JS, Kafrissen ME, Jones TM, Jorizzo JL. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol 1997;89:615-22.
90. Estrostep, NDA 21-276 Final labeling. New York: Pfizer; 2001.
91. Williams J. Noncontraceptive benefits of oral contraceptive use: an evidence-based approach. Int J Fertil Womens Med 2000;45:241-7.
92. Michaelsson K, Baron JA, Farahmand BY, Persson I, Ljunghall S. Oral-contraceptive use and risk of hip fracture: a case-control study. Lancet 1999;353:1481-4.
93. Pasco JA, Kotowicz MA, Henry MJ, Panahi S, Seeman E, Nicholson GC. Oral contraceptives and bone mineral density: a population-based study. Am J Obstet Gynecol 2000;182:265-9.
94. Pladevall-Vila M, Delclos GL, Varas C, Guyer H, Brugues-Tarradellas J, Anglada-Arisa A. Controversy of oral contraceptives and risk of rheumatoid arthritis: meta-analysis of conflicting studies and review of conflicting meta-analyses with special emphasis on analysis of heterogeneity. Am J Epidemiol 1996;144:1-14.
95. Jensen JT, Speroff L. Health benefits of oral contraceptives. Obstet Gynecol Clin North Am 2000;27:705-21.
96. Moore J, Kennedy S, Prentice A. Modern combined oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev 2000;2:CD001019.
97. Luukainen T. The levonorgestrel intrauterine system: therapeutic aspects. Steroids 2000;65:699-702.
98. Fedel L, Bianchi S, Zanconato G, Portuese A, Raffaelli R. Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. Fertil Steril 2001;75:485-8.
99. Luukainen T, Toivonen J. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties. Contraception 1995;52:269-76.
100. Affandi B. An integrated analysis of vaginal bleeding patterns in clinical trials of Implanon. Contraception 1998;58:99S-107S.
101. Zheng SR, Zheng HM, Qian SZ, Sang GW, Kaper RF. A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon) and a six-capsule (Norplant) hormonal contraceptive implant. Contraception 1999;60:1-8.
102. International Collaborative Post-Marketing Surveillance of Norplant. Post-marketing surveillance of Norplant contraceptive implants: I, contraceptive efficacy and reproductive health. Contraception 2001;63:167-86.
103. Kaunitz AM. Injectable contraception: new and existing options. Obstet Gynecol Clin North Am 2000;27:741-80.
104. Holt VL, Daling JR, McKnight B, Moore D, Stergachis A, Weiss NS. Functional ovarian cysts in relation to the use of monophasic and triphasic oral contraceptives. Obstet Gynecol 1992;79:529-33.
105. Young RL, Snabes MC, Frank ML, Reilly M. A randomized, double-blind, placebo-controlled comparison of the impact of low-dose and Triphasic oral contraceptives on follicular development. Am J Obstet Gynecol 1992;167:678-82.